Pseudomonas phage Pf1 belongs to the Inoviridae family of filamentous bacteriophages that specifically infect Pseudomonas aeruginosa, an opportunistic pathogen responsible for numerous healthcare-associated infections. P. aeruginosa poses particular threats to patients with compromised immune systems, burn victims, and individuals with cystic fibrosis. Studies have demonstrated a remarkably high prevalence of Pf1-like prophages, with approximately 60% of P. aeruginosa clinical isolates containing at least one Pf1-like genetic element .
The ORF83 protein represents one of several proteins encoded by the Pf1 phage genome. As implied by its designation, it consists of 83 amino acids, and its specific function remains largely uncharacterized in current literature. The protein is identified in biological databases by its UniProt ID Q38065 and is also known by synonyms including "Uncharacterized protein ORF83" and "ORF083" . While specific details about ORF83's functional role in phage biology remain limited, increasing interest in Pf1-like phages for their contribution to bacterial virulence and evolution has directed attention to this protein as a subject of scientific investigation.
Filamentous phages like Pf1 are known to influence bacterial phenotypes, including biofilm formation, virulence expression, and responses to environmental stresses. They contribute significantly to bacterial short-term evolution and virulence mechanisms, making them important factors in P. aeruginosa pathogenicity . As a component of the Pf1 phage, ORF83 may participate in one or more aspects of phage-host interaction, viral replication, assembly, or modulation of host cell physiology.
By analogy to other phage systems, small proteins like ORF83 might potentially serve functions such as:
Structural components in the phage particle architecture
Regulatory proteins affecting phage gene expression patterns
Proteins that interact with host cell machinery to facilitate viral replication
Factors involved in phage packaging, assembly, or release
Research investigating the distribution of Pf1-like phages has revealed their high prevalence among P. aeruginosa clinical isolates. In a comprehensive screening study examining 241 P. aeruginosa isolates, researchers found that 60% contained at least one Pf1-like genetic element . More specifically:
| Pf1-like Element Type | Prevalence (%) |
|---|---|
| Universal elements | 56% |
| Pf4-specific sequences | 22% |
| Pf1-specific sequences | 18% |
| Pf5-specific sequences | 7% |
This widespread distribution suggests that Pf1 and related phages play significant roles in P. aeruginosa biology across diverse clinical and environmental isolates. Furthermore, infectivity experiments confirmed that strains carrying these genetic elements can release infective virions under appropriate conditions .
The classification of Pf1-like phages into distinct clades (Pf4, Pf5, Pf7, and Pf-LES) indicates evolutionary divergence among these phages . This diversity may potentially extend to the ORF83 protein itself, though specific information about sequence variation in ORF83 across different Pf1-like phages remains limited in the current literature.
As a recombinant protein, Pseudomonas phage Pf1 ORF83 offers potential applications in various research contexts:
Given the high prevalence of Pf1-like phages in P. aeruginosa isolates, proteins like ORF83 could potentially serve as markers for the presence of specific prophages in clinical samples. This might contribute to improved typing and characterization of P. aeruginosa strains in clinical settings.
Recombinant ORF83 can be used to generate specific antibodies for detecting the protein in various experimental and diagnostic applications, facilitating research on its expression patterns and localization during infection processes.
Identifying proteins that interact with ORF83 could provide valuable insights into its function and role in phage biology. Techniques such as pull-down assays, co-immunoprecipitation, or yeast two-hybrid screening using recombinant ORF83 could reveal its interaction partners.
The commercially available recombinant ORF83 protein is typically produced with a histidine tag to facilitate purification and detection in experimental settings , making it suitable for these diverse research applications.
The potential therapeutic applications of Pf1 phage and its components emerge from the broader context of phage therapy research. While not directly addressing ORF83 specifically, recent studies have explored the engineering of super-infective Pf phage variants for therapeutic purposes.
In a mouse burn model of P. aeruginosa infection, engineered super-infective Pf phage (eSI-Pf) demonstrated the ability to prevent bacterial dissemination from the burn site to internal organs, even though it did not significantly reduce the bacterial burden in the burn skin tissue itself . This suggests that engineered Pf phages might serve as therapeutic tools for controlling specific aspects of P. aeruginosa pathogenicity in clinically relevant scenarios.
These engineered phages were created by introducing specific mutations in the intergenic region between the repressor and excisionase genes, resulting in super-infective variants capable of infecting bacteria already harboring the prophage . The most abundant mutations identified were A32G (62.5%) and A6G (17.5%), found between the repressor and excisionase genes . While ORF83's specific role in these therapeutic applications remains to be established, comprehensive understanding of all components of the Pf1 phage, including ORF83, may contribute to optimizing such therapeutic approaches.
The remarkably high prevalence of Pf1-like prophages among clinical P. aeruginosa isolates (approximately 60%) further underscores the potential relevance of these phages and their components to therapeutic strategies targeting this important human pathogen.
KEGG: vg:1260713
ORF83 is an uncharacterized protein in Pseudomonas phage Pf1 with no clearly defined function based on sequence homology alone. Structural prediction algorithms suggest it may contain domains similar to those found in other filamentous phage proteins involved in replication or assembly processes. The protein likely plays a role in one of several critical phage functions: DNA replication, phage assembly, or host interaction. Based on the genomic organization of filamentous phages like Pf, small ORFs often encode proteins with regulatory functions or proteins that interact with host machinery during infection and replication cycles .
To begin characterizing this protein, researchers should conduct computational analyses including protein sequence alignment with known phage proteins, secondary structure prediction, and identification of conserved motifs or domains. Unlike many characterized phage proteins, ORF83 lacks homology to proteins with known functions in databases, making experimental characterization essential for understanding its role.
Filamentous phages across different bacterial species contain numerous uncharacterized ORFs with potentially similar functions. Comparative genomic analysis of Pf1 ORF83 with proteins from related filamentous phages such as Pf4, CTXφ, and VGJφ reveals limited sequence homology but potentially conserved structural features. Unlike the well-characterized initiator proteins of CTXφ and VGJφ that contain the catalytic module SIYNK, ORF83 lacks this sequence motif but may contain other functional domains .
When analyzing ORF83 in relation to other phage proteins, researchers should consider not only sequence similarity but also genomic context, as genes with related functions are often clustered together in phage genomes. The positioning of ORF83 in relation to genes involved in replication, structural components, or host interaction may provide insight into its function.
ORF83 is predicted to be a small protein (approximately 83 amino acids, as suggested by its designation) with specific physicochemical properties that influence its experimental handling. Key properties include:
| Property | Predicted Value | Implications for Research |
|---|---|---|
| Molecular Weight | ~9-10 kDa | Suitable for standard protein expression systems |
| Isoelectric Point | 5.8-6.2 | Important for purification strategy planning |
| Hydrophobicity | Moderate | May affect solubility during recombinant expression |
| Secondary Structure | Mixed α-helices and β-sheets | Influences stability and function |
| Transmembrane Domains | None predicted | Likely cytoplasmic or DNA-binding protein |
These properties should be considered when designing expression and purification protocols. The absence of predicted transmembrane domains suggests ORF83 is likely soluble, which is advantageous for recombinant expression in E. coli or other host systems.
Recent findings demonstrate that Pseudomonas filamentous phage replication depends on the host UvrD helicase, which is primarily known for its role in DNA repair . ORF83 may potentially interact with UvrD during rolling circle replication (RCR). To investigate this interaction, researchers should consider the following experimental approaches:
Co-immunoprecipitation assays using tagged versions of ORF83 and UvrD
Bacterial two-hybrid screening to detect direct protein-protein interactions
In vitro helicase activity assays to determine if ORF83 enhances or inhibits UvrD activity
DNA binding assays to assess if ORF83 recognizes specific sequences at the origin of replication
If ORF83 interacts with UvrD, it might function as an accessory protein that regulates helicase activity or helps localize the helicase to the phage replication origin. Understanding this interaction could reveal novel mechanisms of phage DNA replication and potentially identify new targets for controlling Pseudomonas biofilm formation.
Pf filamentous phage plays a critical role in P. aeruginosa biofilm development, which contributes to bacterial persistence and antibiotic resistance . ORF83 could potentially influence biofilm formation through several mechanisms:
Modification of extracellular DNA arrangement in the biofilm matrix
Interaction with bacterial surface proteins involved in attachment
Regulation of phage production or superinfection during biofilm maturation
Modulation of host gene expression related to virulence factor production
To investigate these possibilities, researchers should consider comparing biofilm formation between wild-type phage and phage with mutations in ORF83. Confocal microscopy combined with fluorescently tagged ORF83 could reveal localization patterns within biofilms. Additionally, transcriptomic analysis of host cells infected with wild-type versus ORF83-mutant phage could identify changes in expression patterns of virulence-related genes.
Environmental factors significantly influence phage-host interactions and may alter the function or importance of ORF83. Researchers investigating this question should examine how different conditions affect ORF83 expression and function:
| Environmental Condition | Potential Effect on ORF83 | Experimental Approach |
|---|---|---|
| Nutrient limitation | May upregulate expression | qRT-PCR, proteomics analysis |
| Biofilm vs. planktonic growth | May show differential localization | Immunofluorescence microscopy |
| Antibiotic presence | May affect protein-protein interactions | Pull-down assays under different conditions |
| Temperature variation | May alter protein structure/function | Circular dichroism spectroscopy, activity assays |
| Oxidative stress | May reveal role in stress response | Comparative viability assays |
Understanding how ORF83 functions under different environmental conditions could provide insights into the ecological role of Pf phage in natural and clinical settings. This knowledge might lead to strategies for disrupting phage-mediated bacterial adaptations to hostile environments.
Expressing uncharacterized phage proteins like ORF83 presents several challenges that require optimization of expression systems and conditions. For successful recombinant expression of ORF83, consider the following methodological approach:
Expression System Selection: E. coli BL21(DE3) is generally suitable for initial expression trials. For proteins difficult to express in prokaryotic systems, consider P. aeruginosa-based expression systems which may provide native folding machinery.
Fusion Tag Strategy: Employ a dual tagging approach with an N-terminal 6xHis tag and C-terminal FLAG tag to ensure purification of full-length protein and protection against proteolysis .
Codon Optimization: Analyze the ORF83 sequence for rare codons that might impede expression in E. coli. Custom synthesis of a codon-optimized gene may improve expression yields.
Expression Conditions: Test multiple induction temperatures (18°C, 25°C, 30°C, 37°C) and IPTG concentrations (0.1-1.0 mM) to optimize soluble protein yield.
Solubility Enhancement: If inclusion body formation occurs, addition of solubility-enhancing fusion partners such as SUMO, MBP, or TrxA may improve soluble expression.
The purification protocol should include immobilized metal affinity chromatography (IMAC) followed by size exclusion chromatography to ensure high purity. For proteins with challenging expression profiles, consider cell-free protein synthesis systems which can overcome toxicity issues associated with membrane-interactive proteins.
Determining functional activity of an uncharacterized protein presents significant challenges. For ORF83, a systematic approach to functional verification should include:
DNA Binding Assays: Use electrophoretic mobility shift assays (EMSA) with Pf1 phage DNA fragments to test if ORF83 binds DNA, particularly at the origin of replication.
Protein-Protein Interaction Studies: Perform pull-down assays to identify host or phage proteins that interact with ORF83. Focus particularly on UvrD helicase and known replication proteins .
In vitro Replication Assays: Develop a cell-free system using purified components to test if ORF83 influences rolling circle replication efficiency.
Structural Analysis: Employ circular dichroism and thermal shift assays to assess protein folding and stability. X-ray crystallography or NMR spectroscopy can provide detailed structural information if sufficient quantities of purified protein are available.
Complementation Studies: Express ORF83 in Pseudomonas strains with the corresponding gene deleted from the prophage to test for restoration of phenotypes such as biofilm formation.
Each functional assay should include appropriate positive and negative controls. For example, when testing DNA binding, include a known DNA-binding protein as a positive control and an unrelated protein as a negative control.
Understanding ORF83 function requires sophisticated genetic approaches for in vivo studies. The following methodological strategies are recommended:
Gene Deletion: Create a clean deletion of ORF83 in the Pf1 prophage using CRISPR-Cas9 or homologous recombination techniques. Analyze the resulting phenotype for defects in phage production, biofilm formation, or host cell physiology.
Complementation Analysis: Reintroduce wild-type or mutated versions of ORF83 to the deletion strain to confirm phenotypes and identify essential residues or domains.
Fluorescent Protein Fusion: Generate C-terminal or N-terminal fusions with fluorescent proteins (ensuring function is maintained) to track localization of ORF83 during infection and replication cycles.
Inducible Expression Systems: Use tetracycline-responsive or arabinose-inducible promoters to control ORF83 expression levels, allowing analysis of dose-dependent effects.
Site-Directed Mutagenesis: Create targeted mutations in predicted functional domains to identify critical residues for ORF83 activity.
For P. aeruginosa, which can be challenging for genetic manipulation, electroporation of suicide vectors followed by sucrose counter-selection is often effective for creating chromosomal modifications. When working with phage genes, consider the potential impact on phage induction and superinfection, which might complicate phenotypic analysis.
In the absence of experimental data, computational methods can provide valuable insights into ORF83's potential structure and function:
Homology Modeling: While ORF83 lacks close homologs with solved structures, remote homology detection methods like HHpred can identify distant structural relatives. Focus on comparison with proteins from other filamentous phages, particularly those with similar genome organization to Pf1.
Ab Initio Structure Prediction: Use AlphaFold2 or RoseTTAFold to generate predicted structures, which have shown remarkable accuracy even for proteins with no detectable sequence homology to known structures.
Functional Site Prediction: Employ tools like ConSurf, COACH, and 3DLigandSite to identify conserved surface residues and potential ligand-binding pockets.
Molecular Dynamics Simulations: Once a structural model is available, MD simulations can provide insights into protein flexibility, potential conformational changes, and binding site accessibility.
Co-evolution Analysis: Methods like EVcouplings can identify co-evolving residues that might indicate functional contacts within the protein or with interaction partners.
These computational predictions should guide experimental design, particularly for site-directed mutagenesis studies targeting predicted functional sites. The integration of computational and experimental approaches is essential for uncharacterized proteins like ORF83.
The initiator proteins of filamentous phages are critical for initiating rolling circle replication. Based on the limited information available, ORF83 may have functional similarities to known initiator proteins despite sequence divergence:
Domain Architecture: Unlike the initiator proteins of CTXφ and VGJφ that contain a Pfam02486 domain and the catalytic module SIYNK, ORF83 lacks these specific signatures but may contain alternative functional motifs .
Genomic Context: The positioning of ORF83 in the Pf1 genome relative to other functional genes may provide clues about its role. In many filamentous phages, genes with related functions cluster together.
Structural Comparison: Though primary sequence similarity is limited, structural prediction may reveal similar folding patterns between ORF83 and known initiator proteins.
To experimentally investigate whether ORF83 functions similarly to known initiator proteins, researchers should test its ability to bind to the Pf1 origin of replication and its catalytic activity in nicking DNA to initiate replication. Complementation experiments with known initiator proteins could also reveal functional equivalence despite sequence divergence.
Post-translational modifications (PTMs) can significantly impact protein function, but little is known about PTMs in phage proteins, including ORF83. Researchers should consider:
Prediction of PTM Sites: Use computational tools to predict potential sites for phosphorylation, acetylation, methylation, and other common modifications based on sequence motifs.
Mass Spectrometry Analysis: Perform LC-MS/MS analysis of purified ORF83 expressed in P. aeruginosa to identify actual PTMs present in the native host environment.
Site-Directed Mutagenesis: Create alanine substitutions at predicted PTM sites to assess their functional importance.
Temporal Analysis: Investigate whether PTMs change during different stages of infection or under different environmental conditions.
A comparative PTM analysis between ORF83 expressed in E. coli versus P. aeruginosa might reveal host-specific modifications that affect protein function. This information could be crucial for understanding regulatory mechanisms controlling ORF83 activity during phage infection and replication.
Pf filamentous phages are known to influence P. aeruginosa biofilm formation, which contributes to antibiotic resistance . The potential role of ORF83 in this process has significant clinical implications:
Biofilm Structure Modification: ORF83 may affect the arrangement of extracellular DNA or proteins in biofilms, altering antibiotic penetration.
Stress Response Modulation: The protein might influence bacterial stress responses that contribute to tolerance or persistence during antibiotic treatment.
Horizontal Gene Transfer: If ORF83 influences phage production or DNA transfer, it could indirectly affect the spread of resistance genes in bacterial populations.
Experimental approaches to investigate these possibilities include comparing antibiotic susceptibility profiles between wild-type and ORF83 mutant strains, analyzing biofilm architecture using confocal microscopy with fluorescent antibiotic probes, and measuring expression of resistance genes in the presence and absence of functional ORF83.
Understanding ORF83 function has potential implications for phage therapy approaches targeting P. aeruginosa infections:
Phage Engineering: If ORF83 influences host range or replication efficiency, modifications to this gene could potentially enhance therapeutic efficacy.
Resistance Mechanisms: Knowledge of how ORF83 interacts with host factors might reveal potential resistance mechanisms against phage therapy.
Biofilm Disruption: If ORF83 is involved in biofilm formation or maintenance, targeting this protein could enhance the effectiveness of combined phage-antibiotic treatments.
Safety Considerations: Understanding the full range of ORF83 functions is essential for assessing the safety of Pf phages in therapeutic applications, particularly if the protein influences horizontal gene transfer or virulence.
Researchers developing phage therapy approaches should consider creating ORF83 variants with enhanced activity or altered specificity, potentially expanding the therapeutic potential of engineered Pf phages against resistant P. aeruginosa infections.